Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Polycystic Ovary Syndrome 149Breast Neoplasms 38Prostatic Neoplasms 31Insulin Resistance 30Obesity 23Endometrial Neoplasms 15Neoplasms 14Infertility 14Colorectal Neoplasms 13Pancreatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Anovulation 10Lung Neoplasms 9Neoplasm Metastasis 8Hyperandrogenism 8Glioblastoma 8Diabetes Mellitus 8Squamous Cell Carcinoma of Head and Neck 7Metabolic Syndrome 7Melanoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Head and Neck Neoplasms 5Brain Neoplasms 5Adenocarcinoma 5Weight Loss 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Rectal Neoplasms 4

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × TP53 Y220C Mutation × Metformin × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡